HC Wainwright Issues Negative Estimate for HOWL Earnings

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Investment analysts at HC Wainwright reduced their Q1 2025 EPS estimates for Werewolf Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.43) per share for the quarter, down from their previous estimate of ($0.38). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Werewolf Therapeutics' current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Werewolf Therapeutics' Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($1.56) EPS, FY2028 earnings at ($1.07) EPS and FY2029 earnings at ($0.64) EPS.

A number of other equities analysts have also commented on HOWL. JMP Securities lowered their price target on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating on the stock in a research report on Tuesday, January 14th. Wedbush restated an "outperform" rating and set a $8.00 target price on shares of Werewolf Therapeutics in a research note on Wednesday, March 12th.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL traded down $0.06 during mid-day trading on Monday, reaching $1.08. 106,640 shares of the company's stock were exchanged, compared to its average volume of 377,658. Werewolf Therapeutics has a one year low of $1.03 and a one year high of $6.89. The firm has a market capitalization of $48.19 million, a PE ratio of -0.70 and a beta of 0.37. The business's fifty day simple moving average is $1.33 and its two-hundred day simple moving average is $1.78. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10.

Remove Ads

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

Institutional Trading of Werewolf Therapeutics

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in Werewolf Therapeutics by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 685,989 shares of the company's stock valued at $1,454,000 after purchasing an additional 40,692 shares during the last quarter. Barclays PLC raised its holdings in shares of Werewolf Therapeutics by 130.1% in the 3rd quarter. Barclays PLC now owns 54,810 shares of the company's stock worth $116,000 after purchasing an additional 30,990 shares during the period. State Street Corp raised its holdings in shares of Werewolf Therapeutics by 12.4% in the 3rd quarter. State Street Corp now owns 476,439 shares of the company's stock worth $1,010,000 after purchasing an additional 52,528 shares during the period. Walleye Capital LLC raised its holdings in shares of Werewolf Therapeutics by 10.7% in the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company's stock worth $231,000 after purchasing an additional 10,528 shares during the period. Finally, Levin Capital Strategies L.P. purchased a new position in Werewolf Therapeutics in the 4th quarter valued at approximately $74,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.